Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Clene Inc. CLNN

Healthcare Biotechnology
Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease and multiple sclerosis. It specializes in the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its CNM-Au8... see more

Recent & Breaking News (NDAQ:CLNN)

Clene Nanomedicine Announces Participation in Renmark Virtual Non-Deal Roadshow Series on January 18 and January 23

GlobeNewswire January 11, 2023

Clene Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAg

GlobeNewswire December 27, 2022

Clene Announces Closing of $5 Million Debt Facility from the State of Maryland

GlobeNewswire December 12, 2022

VISIONARY-MS Trial Results Featured in Platform Presentation at PACTRIMS 2022: CNM-Au8® Demonstrated Global Neurological Improvement in Stable MS Patients as Adjunct to Background Disease Modifying Therapies

GlobeNewswire November 28, 2022

Clene Reports Third Quarter 2022 Financial Results and Recent Operating Highlights

GlobeNewswire November 7, 2022

Clene Announces $10.8 Million Registered Direct Offering and $5 Million Debt Facility from the State of Maryland

GlobeNewswire October 31, 2022

Clene Reports Topline Results Demonstrating Survival Signal for CNM-Au8® in Healey ALS Platform Trial

GlobeNewswire October 3, 2022

Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3

GlobeNewswire September 30, 2022

Clene Nanomedicine Presents Updated Long-Term Survival Data from RESCUE-ALS Participants at 2022 AANEM Scientific Conference

GlobeNewswire September 21, 2022

Clene to Present at Upcoming September Investor Conferences

GlobeNewswire August 30, 2022

Clene Reports Positive Topline Results for CNM-Au8® in the Phase 2 VISIONARY-MS Trial in Multiple Sclerosis

GlobeNewswire August 15, 2022

Clene Reports Second Quarter 2022 Financial Results and Recent Operating Highlights

GlobeNewswire August 15, 2022

Clene to Host VISIONARY-MS Results Call and Webcast on August 15

GlobeNewswire August 12, 2022

Clene Receives Positive EMA Opinion on Orphan Drug Designation for CNM-Au8® for the Treatment of ALS

GlobeNewswire July 19, 2022

Clene Reports Significantly Decreased Mortality in RESCUE-ALS Long-Term Open Label Extension Trial

GlobeNewswire July 14, 2022

Clene to Participate in Panel Discussion About Innovations in ALS Presented by Maxim Group and Hosted by M-Vest on June 28

GlobeNewswire June 27, 2022

Clene Salutes Collaboration of ALS Community and Major League Baseball on Lou Gehrig Day

GlobeNewswire June 2, 2022

New Data from Clene's RESCUE-ALS Study to be Presented at 2022 ENCALS Meeting

GlobeNewswire June 1, 2022

Clene Receives $3 Million Loan from State of Maryland to Support Development of Commercial Manufacturing Facility

GlobeNewswire May 19, 2022

Clene to Present at Upcoming Investor Conferences

GlobeNewswire May 16, 2022